Freenome
Freenome Partners With Geisinger to Recruit Patients for Multi-Cancer Screening Study
The Pennsylvania health system will be able to access patients in both urban and rural settings, aiding Freenome's goal to recruit a total of 8,000 individuals.
Freenome Launches Multi-Cancer Detection Study Using Multiomics, Real-World Evidence
The company plans to analyze both traditional and real-world data from about 8,000 individuals to validate and optimize its multi-cancer early detection platform.
Freenome Nets $290M Investment From Roche
The company said the latest influx brings its total funding to more than $1 billion and will help the firm expand its cancer detection platform to multiple tumor types.
Freenome Raises $300M in Series D Financing
The company will use the funding to support commercialization of its blood-based colorectal cancer detection test and to fuel expansion to other tumor types.
Freenome, Siemens Healthineers Partner to ID Blood-Based Breast Cancer Biomarkers
The companies aim to use multiomic and other types of data to identify blood-based biomarkers that can help in the early diagnosis of breast cancer.